Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Ricardo L. Chaves"'
Autor:
L. Clifford McDonald, Vincent B. Young, Mark H. Wilcox, Alison Laufer Halpin, Ricardo L. Chaves
Publikováno v:
mSphere, Vol 9, Iss 8 (2024)
ABSTRACT Although antibiotics remain a cornerstone of modern medicine, the issues of widespread antibiotic resistance and collateral damage to the microbiome from antibiotic use are driving a need for drug developers to consider more tailored, patien
Externí odkaz:
https://doaj.org/article/33b72f52e0354c29a9eb363ba2bf7d44
Autor:
David A Cooper, Damien V Cordery, Roberto Zajdenverg, Kiat Ruxrungtham, Keikawus Arastéh, Frank Bergmann, José L de Andrade Neto, Joseph Scherer, Ricardo L Chaves, Patrick Robinson, study team
Publikováno v:
PLoS ONE, Vol 11, Iss 1, p e0144917 (2016)
Ritonavir-boosted tipranavir (TPV/r) was evaluated as initial therapy in treatment-naïve HIV-1-infected patients because of its potency, unique resistance profile, and high genetic barrier. Trial 1182.33, an open-label, randomized trial, compared tw
Externí odkaz:
https://doaj.org/article/3e5afe97a73d41bda4ee859fcfc3cee1
Autor:
Harm Peters, Ricardo L. Chaves, Micha Levi, Natascia Corti, Dmytro Khadzhynov, Kamal Hamed, Xiaoying Xu
Publikováno v:
British Journal of Clinical Pharmacology. 83:498-509
Aim The objective of this population pharmacokinetic (PK) analysis was to provide guidance for the dosing interval of daptomycin in patients undergoing continuous renal replacement therapy (CRRT). Methods A previously published population PK model fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d9e46512d47a160f3da564828898d374
https://doi.org/10.1111/bcp.13131
https://doi.org/10.1111/bcp.13131
Autor:
Markus Heep, Pierluigi Viale, R. Andrew Seaton, Teresa Santantonio, Rashidkhan Pathan, Enzo Petrelli, Konstantinos N. Malizos, Ricardo L. Chaves, Panagiotis Gargalianos-Kakolyris
Publikováno v:
Journal of Antimicrobial Chemotherapy
BACKGROUND: Osteomyelitis is a complex and heterogeneous group of infections that require surgical and antimicrobial interventions. Because treatment failure or intolerance is common, new treatment options are needed. Daptomycin has broad Gram-positi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b95a0036d79dddb7eb77234462212402
https://doi.org/10.1093/jac/dkt067
https://doi.org/10.1093/jac/dkt067
Autor:
Xiaoying, Xu, Dmytro, Khadzhynov, Harm, Peters, Ricardo L, Chaves, Kamal, Hamed, Micha, Levi, Natascia, Corti
Publikováno v:
British Journal of Clinical Pharmacology
Aim The objective of this population pharmacokinetic (PK) analysis was to provide guidance for the dosing interval of daptomycin in patients undergoing continuous renal replacement therapy (CRRT). Methods A previously published population PK model fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a8f8afe3f3a8ba9878258b8625707e24
https://pubmed.ncbi.nlm.nih.gov/27628437
https://pubmed.ncbi.nlm.nih.gov/27628437
Autor:
A. Karabis, Shaloo Pandhi, Stavros Nikolakopoulos, Katerina Papadimitropoulou, R Andrew Moore, Richard Nixon, Ricardo L. Chaves
Publikováno v:
Arthritis Research & Therapy
Arthritis Research & Therapy, 18. BioMed Central
Arthritis Research & Therapy, 18. BioMed Central
Background Researchers in clinical trials in rheumatoid arthritis (RA) and osteoarthritis (OA) often measure pain levels with a visual analogue scale (VAS). Of interest to clinical practice and future clinical trial design are associations of change
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2fac467631eb7714685b78103af1b69
https://doi.org/10.1186/s13075-016-0972-7
https://doi.org/10.1186/s13075-016-0972-7
Autor:
Alessandro Capone, Víctor José González-Ramallo, Pascal M. Dohmen, Ricardo L. Chaves, Riccardo Utili, Achyut Guleri, Rashidkhan Pathan, R. Andrew Seaton, Markus Heep
Publikováno v:
Journal of Antimicrobial Chemotherapy. 68:936-942
Infective endocarditis (IE) is a complex infection associated with high mortality. Daptomycin, a cyclic lipopeptide antibiotic highly active against Gram-positive bacteria, has recently been incorporated into IE treatment guidelines. This retrospecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6009036ec873b53aad089a2956784e12
https://doi.org/10.1093/jac/dks467
https://doi.org/10.1093/jac/dks467
Autor:
Hans Lehmkuhl, Andres Beiras-Fernandez, Juergen Loeffler, Ricardo L. Chaves, R. Andrew Seaton, Armando Gonzalez-Ruiz
Publikováno v:
Journal of Antimicrobial Chemotherapy
Objectives: To describe the patient populations and infections being treated with daptomycin, as well as the efficacy and safety outcomes. Patients and methods: Data from the European Cubicin Outcomes Registry and Experience (EU-CORE ™ ), retrospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77f9eef5b0c416ac6746a29d2530c3be
https://doi.org/10.1093/jac/dkq528
https://doi.org/10.1093/jac/dkq528
Publikováno v:
Journal of Antimicrobial Chemotherapy
Nosocomial infections caused by enterococci present a challenge for clinicians because treatment options are often limited due to the widespread occurrence of strains resistant to multiple antibiotics, including vancomycin. Daptomycin is a first-in-c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7d1e6d56fb715d40c2a389c1a176e17
https://doi.org/10.1093/jac/dkq087
https://doi.org/10.1093/jac/dkq087
Publikováno v:
Journal of Antimicrobial Chemotherapy
Objectives: Two randomized Phase I studies in separate populations of healthy adult volunteers investigated the pharmacokinetics, safety and tolerability of daptomycin (Cubicin w ; Novartis Pharma AG, Basel, Switzerland) administered as a 2 min intra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8de93b5bac636c9089c5aacecf91a7b8
http://europepmc.org/articles/PMC2692502
http://europepmc.org/articles/PMC2692502